Rituximab Transplant denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab transplant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Rituximab (Transplant)

Blue Cross Blue Shield requires prior authorization for rituximab in transplant-related settings because it is a high-cost specialty biologic administered in clinical settings, and BCBS uses the prior authorization process to verify that the request meets its coverage criteria before approving payment. A prior-auth-required denial typically means the authorization was either not obtained before treatment, was submitted without sufficient clinical detail, or was denied because the submitted information did not satisfy BCBS's coverage criteria for the specific transplant indication requested.

If authorization was denied — rather than simply not submitted — this is an adverse benefit determination that carries full internal appeal and external review rights.

## Your Appeal Rights

Under ACA Section 2719, a denial of prior authorization is an adverse benefit determination subject to internal appeal and independent external review. Under ERISA Section 503, the same applies to employer-sponsored plans. You generally have 180 days from the denial notice to file an internal appeal. If the internal appeal is denied, external review must be requested within four months of the final internal determination. If the clinical need is urgent — for example, a patient facing organ rejection — expedited prior authorization and expedited appeal processes must be available.

## Building a Strong Prior-Auth Appeal

The appeal should address precisely why the prior authorization criteria are met, since the denial was based on a finding that they were not.

Documentation to assemble: - Complete transplant history and current clinical status, documented in the chart - Specific indication being treated (e.g., rejection, desensitization, PTLD), with diagnosis confirmed by the treating transplant physician in writing - Prior treatment record: what has been tried, in what sequence, with dates and outcomes - Prescriber medical-necessity letter that directly addresses each of BCBS's prior authorization criteria by name — do not submit a generic letter - Any clinical urgency documentation if expedited review is appropriate

## Criteria-Mapping Structure

Request BCBS's prior authorization criteria for rituximab in writing — either from BCBS directly or from their provider portal. These criteria are the checklist the medical director used to deny the request.

For each criterion: - Auth criterion: [copy the requirement exactly as written] - Chart documentation: [identify the specific note, lab, or record that satisfies it, with date]

Also cross-reference the FDA prescribing label for rituximab and BCBS's applicable medical policy — prior authorization criteria are typically derived from the medical policy, and both documents may be needed in the appeal submission.